70b15a54b42b6480 Preclinical and Clinical Development Strategy | Reguclin Consulting
top of page
  • Holistic view of Medicinal Product Development

  • Preclinical and Clinical Development Strategy and Execution for early registration of new drugs, complex generics, novel biologics, biosimilars, cannabinoids, advanced therapies and vaccines

  • Innovative regulatory approach for global drug development to optimize the overall cost and accelerate timelines

  • Ex-industry and ex-agency experts brought under same roof

  • Consultants who have represented their drug development expertise at the Scientific advice meetings across the continents

  • Early risk mitigation strategy to expedite product development process

  • Thinking beyond regulatory guidelines yet achieving compliance, patient safety and ethics

Pharmacovigilance.png

Client Testimonial

Dr. Siddharth Chachad is a truly outstanding resource for us at Catawba Research and I am delighted to enthusiastically endorse him.  One example of his outstanding work happened recently when we needed an extra assistance in addressing an FDA inquiry concerning an NDA we were supporting.  Under high pressure to swiftly respond to the FDA's inquiry, Siddharth's ability to deliver a comprehensive and thoroughly researched document in just two days was a key component of our successful response to the inquiry. Siddharth’s commitment to excellence, rapid delivery, and profound understanding of the subject matter played a pivotal role in the overall success of our response.

 

Dr. Chachad’s proficiency and dedication shone brilliantly as he crafted an exceptional document that not only met but exceeded our expectations. Siddharth's professionalism and collaborative spirit were evident throughout the process. He approached the task with meticulous attention to detail, ensuring accuracy and clarity in every sentence. His adeptness at translating complex scientific concepts into showcased his exceptional communication skills.

 

Without a doubt, Dr. Chachad’s exceptional performance significantly contributed to our ability to meet the tight deadline and present a well-crafted response to the FDA's question. His dedication and expertise make him an invaluable asset, and I wholeheartedly recommend Siddharth for any future projects that demand excellence, precision, and an unwavering commitment to success.

Andy Silverman, PhD

COO, Catawba Research

+1 (512) 897-8943

Catawba.png
bottom of page